Provention Bio is a clinical stage biopharmaceutical company. Co.'s primary asset, TZIELD, is approved to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adult and pediatric patients aged eight years and older with Stage 2 T1D. Co. is also developing TZIELD for use in Stage 3 newly diagnosed T1D patients, for which Co. has an ongoing phase three clinical trial, the PROTECT study. Co.'s product portfolio also include: PRV-3279, which is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, an inhibitory Fc receptor for the treatment of systemic lupus erythematosus and for the prevention of immunogenicity of biotherapeutics such as those used in gene therapy. The PRVB average annual return since 2018 is shown above.
The Average Annual Return on the PRVB average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PRVB average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRVB average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|